For full functionality, including active links, we recommend downloading the PDF. Certain interactive features may not operate within the embedded viewer.
Download this PDF file

 

Crossref Citations

1. Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data
Mattia Berton, Sara Bettonte, Felix Stader, Laurent Decosterd, Philip E Tarr, Françoise Livio, Matthias Cavassini, Dominique L Braun, Katharina Kusejko, Anna Hachfeld, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Manuel Battegay, Catia Marzolini, Irene Abela, Karoline Aebi-Popp, Alexia Anagnostopoulos, Manuel Battegay, Enos Bernasconi, Dominique Laurent Braun, Heiner Bucher, Alexandra Calmy, Matthias Cavassini, Angela Ciuffi, Günter Dollenmaier, Matthias Egger, Luigia Elzi, Jan Fehr, Jacques Fellay, Hansjakob Furrer, Christoph Fux, Huldrych Günthard, Anna Hachfeld, David Haerry, Barbara Hasse, Hans Hirsch, Matthias Hoffmann, Irene Hösli, Michael Huber, David Jackson-Perry, Christian Kahlert, Laurent Kaiser, Olivia Keiser, Thomas Klimkait, Roger Dimitri Kouyos, Helen Kovari, Katharina Kusejko, Niklaus Labhardt, Karoline Leuzinger, Begona Martinez de Tejada, Catia Marzolini, Karin J Metzner, Nicolas Müller, Johannes Nemeth, Dunja Nicca, Julia Notter, Paolo Paioni, Giuseppe Pantaleo, Matthieu Perreau, Andri Rauch, Luisa Salazar-Vizcaya, Patrick Schmid, Roberto Speck, Marcel Stöckle, Philip Tarr, Alexandra Trkola, Gilles Wandeler, Maja Weisser, Sabine Yerly
Clinical Infectious Diseases  vol: 78  issue: 1  first page: 98  year: 2024  
doi: 10.1093/cid/ciad495

2. Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
Mattia Berton, Sara Bettonte, Felix Stader, Manuel Battegay, Catia Marzolini
Open Forum Infectious Diseases  vol: 10  issue: 7  year: 2023  
doi: 10.1093/ofid/ofad361

3. Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir
Roland van Rensburg, Tracy Kellermann, Veshni Pillay-Fuentes Lorente, Christiena du Plessis, Catherine Orrell, Innocent Maposa, Chantel Schreuder, Lauren Jennings, Gert van Zyl, Giovanni Schifitto, Eric Decloedt
The Journal of Infectious Diseases  year: 2025  
doi: 10.1093/infdis/jiaf305

4. 12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection
Taylor C. Kress, Priscilla Ajala, Coleton R. Jordan, James Mintz, Rodger MacArthur, Simone Kennard, Galina Antonova, Eric J. Belin de Chantemèle
Vascular Pharmacology  vol: 155  first page: 107288  year: 2024  
doi: 10.1016/j.vph.2024.107288

5. Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study
Sutthipun Suriya, Siriyaporn Wanitchakorn
AIDS Research and Therapy  vol: 22  issue: 1  year: 2025  
doi: 10.1186/s12981-025-00817-6